Is Adicet Bio, Inc. (ACET) a Buy, Sell, or Hold?
Adicet Bio, Inc.
NASDAQ:ACET
$8.83 USD
$0.28 (3.27%)
- Volume
- 119.94K
- Average Volume
- 108.61K
- Market Capitalization
- $82.54M
- P/E Ratio
- -0.59
- Dividend Yield
- 0.00%
- Price Target
- $432.00
- Year High
- $17.44
- Year Low
- $6.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.65
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Chen Schor |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ACET |
| CUSIP | 007002207 |
| CIK | 0001720580 |
| Web | https://www.adicetbio.com |
| Phone | 650 503 9095 |
| Currency | USD |
| Employees | 102 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.10 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.65 |
| Quick Ratio | 7.65 |
| Cash Ratio | 1.98 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -8.53 |
| Price / Cash Flow | -0.90 |
| Price / Book | 0.68 |
Price Target and Rating
| Average Stock Price Forecast | $432.00 |
| High Stock Price Forecast | $608.00 |
| Low Stock Price Forecast | $18.00 |
| Forecast Upside/Downside | -97.96% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 12 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-16.95 |
| Trailing P/E Ratio | -0.59 |
| PEG Ratio | -0.02 |
| P/E Growth | -0.02 |
| Net Income | $-116.8M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -80.35% |
| Return on Assets | -64.25% |
Financials Score
| AltmanZ Score | -4.80 |
| Piotroski Score | 1.00 |
| Working Capital | 121.77M |
| Total Assets | 169.38M |
| Ebit | -108.77M |
| Market Cap | 83.34M |
| Total Liabilities | 29.32M |
Poll Results
About Adicet Bio, Inc. (NASDAQ:ACET) Stock
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The ... company is headquartered in Boston, Massachusetts.
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
2026-07-01 10:41:17
Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference
2026-06-04 14:05:29
Adicet Bio NASDAQ: ACET outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen Schor emphasizing the company's focus on off-the-shelf gamma delta 1 T-cell therapies for autoimmune disease and oncology.
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
2026-05-28 10:40:44
Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Wall Street Analysts Believe Adicet Bio (ACET) Could Rally 319.64%: Here's is How to Trade
2026-05-25 10:56:13
The average of price targets set by Wall Street analysts indicates a potential upside of 319.6% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-13 16:01:00
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2026. “Adicet is approaching a key inflection point as we prepare to report Phase 1 data for prula-cel in mid-year 2026, including data from at least 20 LN and SLE patients with a minimum.
Frequently Asked Questions
-
What is the current Adicet Bio, Inc. (ACET) stock price?
-
Adicet Bio, Inc.(NASDAQ:ACET) stock price is $8.83 in the last trading session. During the trading session, ACET stock reached the peak price of $17.44 while $6.01 was the lowest point it dropped to. The percentage change in ACET stock occurred in the recent session was 3.27% while the dollar amount for the price change in ACET stock was $0.28.
-
ACET's industry and sector of operation?
-
The NASDAQ listed ACET is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ACET?
-
Blake Aftab | Senior Vice President & Chief Scientific Officer
Donald Healey | Chief Technology Officer
Julie Maltzman | Chief Medical Officer
Brian Nicholas Harvey | Chief Financial Officer
Chen Schor | Chief Executive Officer, President & Director -
How many employees does ACET have?
-
Number of ACET employees currently stands at 102. ACET operates from 200 Clarendon Street, Boston, MA 02116, US.
-
Link for ACET official website?
-
Official Website of ACET is: https://www.adicetbio.com
-
How do I contact ACET?
-
ACET could be contacted at phone #650 503 9095 and can also be accessed through its website. ACET operates from 200 Clarendon Street, Boston, MA 02116, US.
-
How many shares of ACET are traded daily?
-
The average number of ACET shares traded daily for last 3 months was 108.61K.
-
What is the market cap of ACET currently?
-
The market value of ACET currently stands at $82.54M with its latest stock price at $8.83